Clinical Trials Logo

Filter by:
NCT ID: NCT00245843 Active, not recruiting - Premature Birth Clinical Trials

Vermont Intervention: Effect on Joint Attention Skills Between Parents and Moderate/Late Preterm Infants in the First Year of Life

Start date: January 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate if the effects of the Vermont intervention, implemented by nurses in a Neonatal Intensive Care Unit (NICU), can influence social interaction and joint attention skills between parents and preterm babies in the second half of the first year of life.

NCT ID: NCT00245817 Completed - Depression Clinical Trials

HINCAB-study. Home Based Intervention in Nursing for Coronary Artery Bypass Patients

Start date: August 2003
Phase: N/A
Study type: Interventional

HINCAB-study is a single senter, prospective, randomised controlled trial. The aim of the study is to test the effect of a home based intervention program. The hypothesis of the study is that a home based intervention will influencing coping strategies in the CABG-patients rehabilitation phase, reduce symptoms and improve health related quality of life.

NCT ID: NCT00244530 Completed - Clinical trials for Coronary Artery Disease

Prophylactic Effect of Nifedipine on Further Decline in Renal Function in Patients Undergoing Open-Heart Surgery

Start date: June 2001
Phase: Phase 4
Study type: Interventional

To compare renal function (51Cr-EDTA clearance) 48 hours post open-heart surgery (coronary bypass or valve surgery) in patients with impaired renal function after randomization to either nifedipine infusion at start of surgery and the following 24 hours or placebo (0.9% saline infusion). Study hypothesis is that nifedipine has a prophylactic effect on decline in renal function.

NCT ID: NCT00243256 Completed - Obesity Clinical Trials

Treatment of Obesity With Vitamin D (40.000 IE Per Week for 1 Year)

Start date: November 2005
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate if supplementation with vitamin D in doses of 20.000IU per week and 40.000 IU per week will result in weight loss in obese subjects as compared to placebo during 1 year.

NCT ID: NCT00243178 Terminated - Atrial Fibrillation Clinical Trials

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

Start date: July 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if the combination of Clopidogrel 75mg once daily (od) plus aspirin at 100mg daily (recommended dose) is as effective as oral anticoagulation therapy with a lower risk of bleeding in patients with atrial fibrillation associated with at least one major cardiovascular risk factor.Primary objectives :The combination of clopidogrel plus aspirin compared to adjusted dose (INR between 2.0 and 3.3) oral anticoagulation (a vitamin K antagonist) will result in the same risk of the composite outcome of stroke, non-CNS systemic embolism, myocardial infarction or vascular death in patients with atrial fibrillation.The secondary objective is to establish whether or not aspirin plus clopidogrel has a lower risk of hemorrhage than standard anticoagulation therapy.

NCT ID: NCT00242866 Completed - Migraine Disorders Clinical Trials

Use Of GW274150 In The Prophylactic Treatment Of Migraine

Start date: October 2005
Phase: Phase 2
Study type: Interventional

Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO. Reduction of NOS, and therefore NO, may be an effective technique for the prevention of migraine headache. GW274150 is a highly selective inhibitor of NOS and offers the potential of anti-inflammatory activity in migraine through a novel mechanism of action. The intent of this study is to investigate the safety and efficacy of GW274150 for the prophylactic treatment of migraine headache.

NCT ID: NCT00242801 Completed - NSCLC Clinical Trials

Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study

Start date: July 2003
Phase: Phase 3
Study type: Interventional

This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease has recurred after previous chemotherapy treatment.

NCT ID: NCT00242411 Completed - Asthma Clinical Trials

MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults

Start date: September 2004
Phase: Phase 4
Study type: Interventional

The purpose of the study is to compare the efficacy of a flexible dose of Symbicort (budesonide/formoterol) with conventional stepwise best standard treatment in patients with persistent asthma.

NCT ID: NCT00241553 Completed - NSAIDs Clinical Trials

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Start date: April 2001
Phase: Phase 3
Study type: Interventional

This study was a multicentre, double-blind, randomised, placebo-controlled parallel group study consisting of 4 visits over a period of 6 months. The primary variable was to assess theefficacy of esomeprazole 40 mg orally qd (E40) or esomeprazole 20 mg orally qd (E20) versus placebo orally qd after 6 months of treatment for the prevention of relapse of upper GI symptoms associated with NSAID use, including COX-2 selective NSAIDs, in patients receiving daily NSAID therapy.

NCT ID: NCT00241527 Completed - NSAIDs Clinical Trials

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Start date: December 2000
Phase: Phase 3
Study type: Interventional

This study was a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs placebo and esomeprazole 20 mg orally qd vs placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a treatment period of 4 weeks for relief of upper GI symptoms.